FDA approves weight-management drug Contrave
The U.S. Food and Drug Administration today approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Bupropion | Food and Drug Administration (FDA) | Nutrition | Wellbutrin